Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA-3)

Category Primary study
JournalBLOOD
Year 2024
This article has no abstract
Epistemonikos ID: 0cdc2669f5eb190f056cad3f40271733afa4a354
First added on: Jul 12, 2025